We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Centene Expands Palliative Care Access in Ohio Through Tuesday Health
Read MoreHide Full Article
Key Takeaways
Centene's Buckeye Health Plan now offers structured palliative care with Tuesday Health.
Members get 24/7 access to nurses, social workers and physicians for symptom support.
The program aims to reduce ER visits and improve care coordination in Ohio.
Centene Corporation (CNC - Free Report) is broadening its supportive care services in Ohio through a new partnership between its Buckeye Health Plan subsidiary and Tuesday Health. Launched on Jan. 1, 2026, this initiative aims to provide structured palliative care for members facing serious illnesses by blending in-person support with virtual access to enhance the continuity of care and overall patient experience.
Under this program, eligible Buckeye members receive support from Tuesday Health’s diverse teams, which include nurses, social workers, nurse practitioners and physicians. These teams collaborate closely with current providers to manage symptoms, clarify care objectives and assist caregivers in navigating complex treatment pathways. With 24/7 access to clinicians, it aims to tackle issues early on, which can help prevent unnecessary hospital admissions.
The partnership is timely as Ohio continues to face rising caregiver strain and a growing population with complex medical needs. Palliative care complements ongoing treatments by focusing on comfort and coordination. By tackling symptoms early and providing steady support, these programs can help reduce unnecessary emergency room visits, giving both patients and caregivers a clearer path and confidence in care decisions.
This move aligns well with CNC’s broader value-based care strategy. Medicaid, Medicare Advantage and dual-eligible plan populations typically account for higher medical costs, making early intervention models financially relevant. Meanwhile, given Tuesday Health’s track record of high engagement and lower hospital usage, this partnership could help manage medical costs in the medium term while also improving patient outcomes.
Strategically, the Ohio rollout also creates a scalable framework. If performance metrics meet expectations, Centene might expand similar partnerships across its various states. While the immediate financial impact might not be huge, this initiative could boost the company’s role in whole-person care and reinforce its long-term commitment to managing complex populations with coordinated, community-focused solutions.
CNC’s Price Performance
Over the past three months, CNC shares have gained 23.8% against the industry’s decline of 6.8%.
The Zacks Consensus Estimate for Krystal Biotech’s current-year earnings of $6.45 per share has remained stable in the past seven days. Krystal Biotech beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 40.4%. The consensus estimate for current-year revenues is pegged at $388.3 million, suggesting 33.7% year-over-year growth.
The Zacks Consensus Estimate for Veracyte’s current-year earnings of $1.66 per share has witnessed one upward revision in the past seven days, against no movement in the opposite direction. Veracyte beat earnings estimates in each of the trailing four quarters, with the average surprise being 45.1%. The consensus estimate for current-year revenues is pegged at $510.1 million, suggesting 14.4% year-over-year growth.
The Zacks Consensus Estimate for Fortress Biotech’s current-year earnings of 71 cents per share has witnessed one upward revision in the past 60 days, against no movement in the opposite direction. Fortress Biotech beat earnings estimates in two of the trailing four quarters and missed twice, with an average surprise of 33.8%. The consensus estimate for current-year revenues is pegged at $80.7 million, suggesting 39.9% year-over-year growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Centene Expands Palliative Care Access in Ohio Through Tuesday Health
Key Takeaways
Centene Corporation (CNC - Free Report) is broadening its supportive care services in Ohio through a new partnership between its Buckeye Health Plan subsidiary and Tuesday Health. Launched on Jan. 1, 2026, this initiative aims to provide structured palliative care for members facing serious illnesses by blending in-person support with virtual access to enhance the continuity of care and overall patient experience.
Under this program, eligible Buckeye members receive support from Tuesday Health’s diverse teams, which include nurses, social workers, nurse practitioners and physicians. These teams collaborate closely with current providers to manage symptoms, clarify care objectives and assist caregivers in navigating complex treatment pathways. With 24/7 access to clinicians, it aims to tackle issues early on, which can help prevent unnecessary hospital admissions.
The partnership is timely as Ohio continues to face rising caregiver strain and a growing population with complex medical needs. Palliative care complements ongoing treatments by focusing on comfort and coordination. By tackling symptoms early and providing steady support, these programs can help reduce unnecessary emergency room visits, giving both patients and caregivers a clearer path and confidence in care decisions.
This move aligns well with CNC’s broader value-based care strategy. Medicaid, Medicare Advantage and dual-eligible plan populations typically account for higher medical costs, making early intervention models financially relevant. Meanwhile, given Tuesday Health’s track record of high engagement and lower hospital usage, this partnership could help manage medical costs in the medium term while also improving patient outcomes.
Strategically, the Ohio rollout also creates a scalable framework. If performance metrics meet expectations, Centene might expand similar partnerships across its various states. While the immediate financial impact might not be huge, this initiative could boost the company’s role in whole-person care and reinforce its long-term commitment to managing complex populations with coordinated, community-focused solutions.
CNC’s Price Performance
Over the past three months, CNC shares have gained 23.8% against the industry’s decline of 6.8%.
Image Source: Zacks Investment Research
CNC’s Zacks Rank & Key Picks
CNC currently carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the Medical space are Krystal Biotech, Inc. (KRYS - Free Report) , Veracyte, Inc. (VCYT - Free Report) and Fortress Biotech Inc (FBIO - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Krystal Biotech’s current-year earnings of $6.45 per share has remained stable in the past seven days. Krystal Biotech beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 40.4%. The consensus estimate for current-year revenues is pegged at $388.3 million, suggesting 33.7% year-over-year growth.
The Zacks Consensus Estimate for Veracyte’s current-year earnings of $1.66 per share has witnessed one upward revision in the past seven days, against no movement in the opposite direction. Veracyte beat earnings estimates in each of the trailing four quarters, with the average surprise being 45.1%. The consensus estimate for current-year revenues is pegged at $510.1 million, suggesting 14.4% year-over-year growth.
The Zacks Consensus Estimate for Fortress Biotech’s current-year earnings of 71 cents per share has witnessed one upward revision in the past 60 days, against no movement in the opposite direction. Fortress Biotech beat earnings estimates in two of the trailing four quarters and missed twice, with an average surprise of 33.8%. The consensus estimate for current-year revenues is pegged at $80.7 million, suggesting 39.9% year-over-year growth.